HBF - MCV - HB. Generated by Foxit PDF Creator Foxit Software For evaluation only.
|
|
|
- Jodie Perkins
- 5 years ago
- Views:
Transcription
1 Tishreen University Journal for Research and Scientific Studies - Medical Sciences Series Vol. (0) No. ( ) HB ٩٩
2 Tishreen University Journal for Research and Scientific Studies - Medical Sciences Series Vol. (0) No. ( ) 008 Hydroxyurea in the Treatment of Sickle Cell Disease (Received 7 / / 008. Accepted 4/8/008) ABSTRACT Dr. Michael Georgeos * Dr. Ryad Galek** Youla Ahmad*** This study aims to assess the laboratory and clinical benefits of hydroxyurea in the treatment of sickle cell disease. This study includes (0 ) patients of SCD who had reported at least three painful crises in the previous year, or had reported at least three transfusions or hospitalization in a year, or who had a history of stroke, acute chest syndrome or splenic sequestration, or who had systemic sever anemia. Hydroxyurea was gradually increased from an initial dose of mg / kg / d to 0 mg / kg / d. These patients were monitored by -month visits for one year to assess laboratory changes and clinical efficacy. Significant hematologic changes included increase in (HB - - ) and decrease in. And there was decrease in the number of transfusions, and painful crises. However, there were five patients who did not show any response to the treatment and the concentration did not increase more than % after a treatment for one year. Key words: Hydroxyurea, sickle cell disease, painful crises, recurent hospitalaization, fetal hemoglobin. * prof, Medical Department, Faculty of medicine, Tishreen University, Lattakia, Syria. **Associate prof, Department of Internal Disease, Faculty of Medicine, Tishreen University, Lattakia, Syria. ***postgraduate student, Department of Internal Disease, Faculty of Medicine, Tishreen University, Lattakia, Syria. ٠
3 Tishreen University Journal. Med. Sciences Series alpha, beta S S β S [] γ, α [] S γ α β [] HbF [] HbF SCD [4] SCD [] ] ١
4 4 4 0 HB -HB HB HB p i x HB ) S X [] X Pi xi Pi, S Pi ( xi x) Pi X S ٢
5 Tishreen University Journal. Med. Sciences Series X X i P i 00 HB p i ( ( ٣
6 بدء الدراس ة بعد ٦ أشھر بعد عام مریض ١ مریض ٢ مریض ٣ مریض ٤ مریض ٥ مریض ٦ مریض ٧ مریض ٨ مریض ٩ مریض ١٠ مریض ١١ مریض ١٢ مریض ١٣ مریض ١٤ مریض ١٥ مریض ١٦ مریض ١٧ مریض ١٨ مریض ١٩ مریض ٢٠ مریض ٢١ مریض ٢٢ مریض ٢٣ مریض ٢٤ مریض ٢٥ ٤
7 Tishreen University Journal. Med. Sciences Series بعد عام بعد ٦ أشھر بدء الدراسة مریض ١ مریض ٢ مریض ٣ مریض ٤ مریض ٥ مریض ٦ مریض ٧ مریض ٨ مریض ٩ مریض ١٠ مریض ١١ مریض ١٢ مریض ١٣ مریض ١٤ مریض ١٥ مریض ١٦ مریض ١٧ مریض ١٨ مریض ١٩ مریض ٢٠ مریض ٢١ مریض ٢٢ مریض ٢٣ مریض ٢٤ مریض ٢٥ ٥
8 p i ( 4 4 ٦
9 Tishreen University Journal. Med. Sciences Series بدء الدراسة بعد ٦ أشھر بعد عام مریض ١ مریض ٢ مریض ٣ مریض ٤ مریض ٥ مریض ٦ مریض ٧ مریض ٨ مریض ٩ مریض ١٠ مریض ١١ مریض ١٢ مریض ١٣ مریض ١٤ مریض ١٥ مریض ١٦ مریض ١٧ مریض ١٨ مریض ١٩ مریض ٢٠ مریض ٢١ مریض ٢٢ مریض ٢٣ مریض ٢٤ مریض ٢٥ ٧
10 بدء الدراسة بعد ٦ أشھر بعد عام مریض ١ مریض ٢ مریض ٣ مریض ٤ مریض ٥ مریض ٦ مریض ٧ مریض ٨ مریض ٩ مریض ١٠ مریض ١١ مریض ١٢ مریض ١٣ مریض ١٤ مریض ١٥ مریض ١٦ مریض ١٧ مریض ١٨ مریض ١٩ مریض ٢٠ مریض ٢١ مریض ٢٢ مریض ٢٣ مریض ٢٤ مریض ٢٥ ٨
11 Tishreen University Journal. Med. Sciences Series 00 HB ).±.±..+_.) +_.) 44 4 (. 7 ٩
12 7.+_0.8) HB (8) ٠
13 Tishreen University Journal. Med. Sciences Series متوسط قیم HB 0 بعد عام بعد ٦ أشھر عند بدء الدراسة بدء الدراسة بعد ٦ أشھر بعد عام متوسط قیم ١
14 بدء الدراسة متوسط بعد عام بعد ٦ أشھر ) Fetal hemaglobin in sickle cell anemia : Determinants of Respanse to Hydroxyurea(7) ) Five years of experience with hydroxyurea in children and young adults with sickle cell disease (8) ) Fetal hemoglobin f-cell Respanses to long term hydroxyurea Treatment in Young Sickle cell patients.(9) ٢
15 Tishreen University Journal. Med. Sciences Series 0 /B-Thal /B -Thal S! safty of hydroxyurea in children with sickle cell Anemia (0) HB F ٣
16 HB ٤
17 Tishreen University Journal. Med. Sciences Series - BUNN,H.F. pathogenesis and treatment of sickle cell disease. N Engl J Med, 997, 7:7. - VICHINSKY, E. New therapies in sickle cell disease. Lancet, 00, 0:9. - CHARACHE, S; TERRIN, M; Moore, R. Effect of hydroxyurea on the frequency of painful crisis in sickle cell anemia. N Engl J Med, 99, : CHARACHE, S; DOVER, G; MOYER, M. Hydroxyurea - induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood, 987, 9: MARTIN, H. Current use of hydroxy urea in sickle cell diseas. Hematol, : MARTIN, H, FRANCA, B, MICHAEL, L fetal hemoglobine in sickle cell anemia;determinants of response to hydroxyurea. BLOOD vol. 89no. (february)997; ALINA, F, CHRISTIANE, V, KATHLEEN, H five years of experience with hydroxyurea in children and young adults with sickl e cell disease. BLOOD vol.79no.(june),00; MICHELINE, M. ANTOINE, ROBERT,G. fetal hemoglobin and f-cell responses to long -term hydroxyurea treatment in young sickle cell patients. BLOOD, vol. 9no.(juneis),998; THOMAS, R, RONALD,w, HELMS, E.saftey of hydroxyurea in children with sickle cell anemia BLOOD,vol94no. (septemper),999; 0-4 ٥
18 ٦
HU: Myths and Facts. Melanie Kirby Associate Professor of Paediatrics
HU: Myths and Facts Melanie Kirby Associate Professor of Paediatrics SACGO Hamilton, Ontario March 5, 2016 Declaration of Disclosure I have no actual or potential conflict of interest in relation to this
Anemia s. Troy Lund MSMS PhD MD
Anemia s Troy Lund MSMS PhD MD lundx072@umn.edu Hemoglobinopathy/Anemia IOM take home points. 1. How do we identify the condtion? Smear, CBC Solubility Test (SCD) 2. How does it present clincally? 3. How
Hydroxyurea Treatment for Sickle Cell Disease
Hydroxyurea Treatment for Sickle Cell Disease Before Hydroxyurea After Hydroxyurea Hydroxyurea Treatment for Sickle Cell Disease This document is not intended to take the place of the care and attention
Hydroxurea: A Novel Approach to Optimizing the Health of Pediatric Patients with Sickle Cell Disease. Maa Ohui Quarmyne September 9 th, 2017
Hydroxurea: A Novel Approach to Optimizing the Health of Pediatric Patients with Sickle Cell Disease Maa Ohui Quarmyne September 9 th, 2017 Outline Sickle Cell Disease Pathophysiology and Clinical Manifestations
Hydroxyurea Treatment for Sickle Cell Disease
Hydroxyurea Treatment for Sickle Cell Disease Hydroxyurea Treatment for Sickle Cell Disease 1 This document is not intended to take the place of the care and attention of your personal physician. Our aim
New England Pediatric Sickle Cell Consortium
New England Pediatric Sickle Cell Consortium Use of Hydroxyurea in Pediatric Patients with Sickle Cell Disease Prepared by: Kathleen Ryan, RN, MPH, and Matthew Heeney, MD. Reviewed by: New England Pediatric
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease A Pocket Guide for the Clinician Susan E. Creary, MD, MSc 1 John J. Strouse, MD, PhD 2 1 The Ohio State University School of
Transfusion in Sickle Cell Disease What the guidelines [are likely to] say. Dr Bernard Davis Whittington Hospital, London
![Transfusion in Sickle Cell Disease What the guidelines [are likely to] say. Dr Bernard Davis Whittington Hospital, London](/thumbs/85/91702350.jpg "Transfusion in Sickle Cell Disease What the guidelines [are likely to] say. Dr Bernard Davis Whittington Hospital, London")
Transfusion in Sickle Cell Disease What the guidelines [are likely to] say Dr Bernard Davis Whittington Hospital, London Background to BCSH Guideline Rationale Current guidance in disparate publications
Sickle Cell Disease Why Is A Simple Genetic Disorder So Hard To Treat And How Are We Doing?
Sickle Cell Disease Why Is A Simple Genetic Disorder So Hard To Treat And How Are We Doing? James R. Eckman, MD Professor of Medicine, Hematology and Oncology Winship Cancer Institute Emory University
The Effect of Hydroxyurea Treatment on Fetal Haemoglobin Level and Clinical Status of Sudanese Sickle Cell Anaemia Patients
EUROPEAN ACADEMIC RESEARCH Vol. II, Issue 6/ September 2014 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.1 (UIF) DRJI Value: 5.9 (B+) The Effect of Hydroxyurea Treatment on Fetal Haemoglobin Level
Cost-effectiveness of hydroxyurea in sickle cell anemia Moore R D, Charache S, Terrin M L, Barton F B, Ballas S K
Cost-effectiveness of hydroxyurea in sickle cell anemia Moore R D, Charache S, Terrin M L, Barton F B, Ballas S K Record Status This is a critical abstract of an economic evaluation that meets the criteria
A bout 170 babies are born annually in the UK with sickle
325 Coping and health service utilisation in a UK study of paediatric sickle cell pain K A Anie, A Steptoe, S Ball, M Dick, B M Smalling... Seeletteronp385 See end of article for authors affiliations...
Siklos (hydroxyurea) NEW PRODUCT SLIDESHOW
Siklos (hydroxyurea) NEW PRODUCT SLIDESHOW Introduction Brand name: Siklos Generic name: Hydroxyurea Pharmacological class: Antimetabolite Strength and Formulation: 100mg, 1000mg+; tabs; +triple-scored
Sickle cell disease. Fareed Omar 10 March 2018
Sickle cell disease Fareed Omar 10 March 2018 Physiology Haemoglobin structure HbA2: 2α and 2δ chains (2-3%) HbF: 2α and 2γ chains (
Genetic Modifiers of Sickle Cell Disease Severity. Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University
Genetic Modifiers of Sickle Cell Disease Severity Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University Outline Hb Molecule and Genetic control of globin synthesis Pathophysiology
Medical and Surgical Complications of Sickle Cell Anemia
Medical and Surgical Complications of Sickle Cell Anemia Ahmed Al-Salem Medical and Surgical Complications of Sickle Cell Anemia Ahmed Al-Salem Department of Surgery Dar A lalafia Medical Company Qatif
Transfusions in Sickle Cell Disease: How, When and Why
Transfusions in Sickle Cell Disease: How, When and Why James R. Eckman, MD Professor Emeritus of Hematology and Medical Oncology Emory University School of Medicine This work is supported by the Centers
Sickle Cell Anemia A Fictional Reconstruction Answer Key
We have made it easy for you to find a PDF Ebooks without any digging. And by having access to our ebooks online or by storing it on your computer, you have convenient answers with sickle cell anemia a
SICKLE CELL BROCHURE
SICKLE CELL BROCHURE SICKLE CELL DIESEASE According to CDC, Sickle cell disease (SCD) is a group of inherited red blood cell disorders. Healthy red blood cells are round and SCD C -shaped farm tool called
Hematological profile among Sudanese patients with sickle cell anemia
EUROPEAN ACADEMIC RESEARCH Vol. III, Issue 4/ July 2015 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Hematological profile among Sudanese patients with sickle cell
Hemoglobinopathies NORMAL HEMOGLOBINS
Hemoglobinopathies Millicent Sutton MD October 28, 2005 NORMAL HEMOGLOBINS Consist of 2 alpha chains and 2 non alpha chains Hb A = α2β2 Hb F= α 2γ2 Hb A2 = α2δ2 1 Hemoglobin Variants Altered the conformational
Hospitalization Rates and Costs of Care of Patients With Sickle-Cell Anemia in the State of Maryland in the Era of Hydroxyurea
American Journal of Hematology 81:927 932 (2006) Hospitalization Rates and Costs of Care of Patients With Sickle-Cell Anemia in the State of Maryland in the Era of Hydroxyurea Sophie Lanzkron, 1 * Carlton
Congenital Haemoglobinopathies
Congenital Haemoglobinopathies L. DEDEKEN, MD H O P I T A L U N I V E R S I T A I R E D E S E N F A N T S R E I N E F A B I O L A U N I V E R S I T E L I B R E DE B R U X E L L E S Red Blood Cell Disorders
Detecting and Reporting Alpha Thalassemia In Newborns
Detecting and Reporting Alpha Thalassemia In Newborns T. Davis, C. Moore, L. Nayak, M.C. Dorley, M. del Pilar Aguinaga, M. Chan, J. Ubaike, C. Yusuf Alpha Thalassemia Screening Status in the US Clinical
The Thalassemias in Clinical Practice. Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland
The Thalassemias in Clinical Practice Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland Outline Thalassemia: definitions and pathophysiology Epidemiology
How to Write a Life Care Plan for a Child with Hemoglobinopathy
How to Write a Life Care Plan for a Child with Hemoglobinopathy Tamar Fleischer, BSN, MSN, CNLCP & Mona Yudkoff, RN, MPH, CRRN, CNLCP BalaCare Solutions March 2018 St. Peterburg, Florida What is Hemoglobinopathy?
Hemolytic anemias (2 of 2)
Hemolytic anemias (2 of 2) Sickle Cell Anemia The most common familial hemolytic anemia in the world Sickle cell anemia is the prototypical (and most prevalent) hemoglobinopathy Mutation in the β-globin
Minimal doses of hydroxyurea for sickle cell disease
Brazilian Journal of Medical and Biological Research (1997) 30: 933-940 Minimal HU doses for sickle cell disease ISSN 00-79X 933 Minimal doses of hydroxyurea for sickle cell disease C.S.P. Lima, V.R. Arruda,
Hydroxyurea. for Sickle Cell Disease. A Guide for Starting Treatment. Hydroxyurea is a medicine proven to prevent pain from sickle cell disease.
Hydroxyurea for Sickle Cell Disease A Guide for Starting Treatment Hydroxyurea is a medicine proven to prevent pain from sickle cell disease. This handbook was created to help answer common questions about
Managing Emergencies
Managing Emergencies Richard Ward, MSc, MRCP, FRCPath Director, Red Blood Cell Disorders Program, UHN Assistant Professor, Hematology, University of Toronto Chair, Canadian Hemoglobinopathy Association
Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model
Published Ahead of Print on April 7, 2010, as doi:10.3324/haematol.2010.023325. Copyright 2010 Ferrata Storti Foundation. Early Release Paper Hydroxyurea therapy requires HbF induction for clinical benefit
The Effect of Hydroxyurea on Vasculopathy in a Child with Sickle Cell Disease
AJNR Am J Neuroradiol 23:1692 1696, November/December 2002 Case Report The Effect of Hydroxyurea on Vasculopathy in a Child with Sickle Cell Disease Kathleen J. Helton, Winfred C. Wang, Lynn W. Wynn, Raja
Anaemia in Pregnancy
Anaemia in Pregnancy Definition :anaemia is a pathological condition in which the oxygen-carrying capacity of red blood cells is insufficient to meet the body needs. The WHO : haemoglobin concentration
JIHS. The Journal of Integrated Health Sciences. Role of Hydroxyurea In Management of Sickle Cell Disease. Original Article
JIHS Available online at www.jihs.in The Journal of Integrated Health Sciences Role of Hydroxyurea In Management of Sickle Cell Disease Rakesh Amroliwala 1, Vishruti Gandhi* 2, Niyati Parikh 3, Arti Gupta
A guide to hydroxycarbamide (hydroxyurea)
A guide to hydroxycarbamide (hydroxyurea) This information sheet is intended to help answer questions you may have about taking hydroxycarbamide for the management of sickle cell disease. What is hydroxycarbamide?
Siklos. Siklos (hydroxyurea) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.27 Subject: Siklos Page: 1 of 5 Last Review Date: November 30, 2018 Siklos Description Siklos (hydroxyurea)
Sickle Cell Disease. Edward Malters, MD
Sickle Cell Disease Edward Malters, MD Introduction Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of Sickle Cell Disease (SCD) Inherited disorder due to homozygosity for the abnormal
Effects of monotherapy and combined therapy on LPI
Effects of monotherapy and combined therapy on LPI 14 12 DFO 40 mg/kg/day 14 12 Deferiprone 75 mg/kg/day 14 12 Deferiprone 75 mg/kg/day DFO 40 mg/kg/day DFO 40 mg/kg/day LPI (μm) 10 8 6 LPI (μm) 10 8 6
Is there a rationale for treatment of sickle cell anemia, except for acute complications?
Is there a rationale for treatment of sickle cell anemia, NO, but JL Vives Corrons Red Cell Pathology Unit Hospital Clnic. University of Barcelona Head of ENERCA Project EUROPEAN NETWORK FOR RARE AND CONGENITAL
Case Report Iron Depletion: An Ameliorating Factor for Sickle Cell Disease?
International Scholarly Research Network ISRN Hematology Volume 2011, Article ID 473152, 4 pages doi:10.5402/2011/473152 Case Report Iron Depletion: An Ameliorating Factor for Sickle Cell Disease? P. C.
Your sickle cell disease story
YOUR STORY Not actual patients. Your sickle cell disease story From the very beginning of sickle cell disease (SCD) to your role in the next chapter Visit GenSickleCell.com to get involved with the movement.
HPLC profile of sickle cell disease in central India
Original Research Article HPLC profile of sickle cell disease in central India Shweta P. Bijwe * Department of Pathology, IGGMC, Nagpur, Maharashtra, India * Corresponding author email: dr.shwetabijwe@gmail.com
FOXO3 Regulates Fetal Hemoglobin Levels in Sickle Cell Anemia. Yankai Zhang, Jacy R. Crosby, Eric Boerwinkle, Vivien A. Sheehan
FOXO3 Regulates Fetal Hemoglobin Levels in Sickle Cell Anemia Yankai Zhang, Jacy R. Crosby, Eric Boerwinkle, Vivien A. Sheehan Sickle Cell Anemia Steinberg MH. N Engl J Med 1999;340:1021-1030. Akinsheye
Sickle Cell Anemia. Sickle cell anemia is an inherited disorder of the blood which occurs when just one base pair substitution
Rose Farrington and Rachel Nash BIOL 362 Lab M. Bulgarella Genetic Diseases 10/14/2008 Sickle Cell Anemia Introduction Sickle cell anemia is an inherited disorder of the blood which occurs when just one
Introduction reduction in output alter the amino acid sequence combination
Sickle cell anemia. Introduction Mutations in the globin genes can cause a quantitative reduction in output from that gene or alter the amino acid sequence of the protein produced or a combination of the
Eighth Visit Posttest
Test code 08B Patient s name: Eighth Visit Posttest Patient s birth date: Your name and relationship to patient: Today s date: Please mark only one answer for each of the following questions: 1. Which
Historic and Current Complications in Children with Sickle Cell Disease
Historic and Current Complications in Children with Sickle Cell Disease Trish McMahon Peterson RN, MSN, CPNP Thomas C. Hofstra MD Children's Hospital Los Angeles Comprehensive Sickle Cell Program Children's
Disclosure. Hemoglobinopathies. Screening for Hemoglobinopthies. Learning Objectives. Screening for Hemoglobinopthies. Interpreting Reports
Disclosure Hemoglobinopathies (everything you wanted to know but were afraid to ask) Melissa Frei-Jones, MD MSCI Pediatric Grand Rounds February 21, 2014 I have no relationships with commercial companies
PART II: PREVENTING AND MANAGING COMPLICATIONS OF SICKLE CELL DISEASE
PART II: PREVENTING AND MANAGING COMPLICATIONS OF SICKLE CELL DISEASE 1. PAIN Principles To educate patients, family and other caregivers about prevention, rapid identification and management of vaso-occlusive
SICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN
SICKLE CELL DISEASE Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN Objective: The student should be able: To identify the presentation, diagnosis,
Effects of Hydroxyurea Hemoglobin F Level in Pediatric Patients with Sickle Cell Disease Attaining Jafaar Ibnouf Hospital - Khartoum
Effects of Hydroxyurea Hemoglobin F Level in Pediatric Patients with Sickle Cell Disease Attaining Jafaar Ibnouf Hospital - Khartoum Tariq E. Elmissbah* and Mohammed A. Abdalla Department of Medical Laboratory,
Rationale for RBC Transfusion in SCD
Rationale for RBC Transfusion in SCD Dilution of HgbS-containing RBCs via the addition of HgbA-containing cells from the blood of normal donors Suppression of erythropoietin release caused by the rise
Division of General Internal Medicine and Geriatrics Hospital Medicine 2014
Division of General Internal Medicine and Geriatrics Hospital Medicine 2014 Objectives Understand workup of acute pain crisis Identify key aspects of management of acute pain crisis in sickle cell patients
DONE BY : RaSHA RAKAN & Bushra Saleem
DONE BY : RaSHA RAKAN & Bushra Saleem Hemolytic anemias (2 of 2) Sickle Cell Anemia The most common familial hemolytic anemia in the world Sickle cell anemia is the prototypical (and most prevalent) hemoglobinopathy
DRUG FORECAST. 50% fewer transfusions and hospitalizations. 2,3,5
Hydroxyurea in the Treatment of Sickle Cell Anemia Tarrah Williams, PharmD Candidate, Marlon Honeywell, PharmD, Evans Branch III, PharmD, Zandra Glenn, PharmD, and Fran Close, PhD Tarrah Williams is a
Making Hope A Reality December 10, Nasdaq : BLUE
Making Hope A Reality December 10, 2014 Nasdaq : BLUE Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words
SICKLE CELL DISEASE TO TREAT OR
SICKLE CELL DISEASE TO TREAT OR NOT TO TREAT COHEM Barcelona September 8, 2012 Sujit Sheth, M.D. Pediatric Hematology Oncology Disclosures None Outline Morbidity and mortality Definitive therapies Risk
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. Risks and Benefits Up to 9 Years of Treatment JAMA. 2003;289:
ORIGINAL CONTRIBUTION Effect of on Mortality and Morbidity in Adult Sickle Cell Anemia Risks and Benefits Up to 9 Years of Treatment Martin H. Steinberg, MD Franca Barton, MS Oswaldo Castro, MD Charles
INFLUENCE OF DELETIONAL ALPHA THALASSEMIA ON CLINICAL AND LABORATORY PARAMETERS OF YOUNG NIGERIANS WITH SICKLE CELL ANAEMIA
INFLUENCE OF DELETIONAL ALPHA THALASSEMIA ON CLINICAL AND LABORATORY PARAMETERS OF YOUNG NIGERIANS WITH SICKLE CELL ANAEMIA Authors:Oladele Simeon Olatunya, 1,2,3, Dulcineia Martins de Albuquerque, 2,
Original Article INTRODUCTION:
Original Article International Journal of Dental and Health Sciences Volume 03,Issue 03 EFFECT OF HEMOGLOBIN AND FERRITIN OF SERUM CONCENTRATIONS ON THE DENSITY OF JAWBONE THAT INTENDED FOR DENTAL IMPLANT
Hydroxyurea and sickle cell anemia: Effect on quality of life
Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine August 2006 Hydroxyurea and sickle cell anemia: Effect on quality of life Samir K. Ballas
Three Decades of Clinical Research in Sickle Cell Disease in the United States
Three Decades of Clinical Research in Sickle Cell Disease in the United States Jane Hankins, MD, MS St. Jude Children s Research Hospital Memphis, TN Outline of Presentation Historical perspective 1972
Hydroxyurea (Hydroxycarbamide) - Guidelines for treating children with Sickle Cell Disease
Hydroxyurea (Hydroxycarbamide) - Guidelines for treating children with Sickle Cell Disease Document Information Version: 2 Date: July 2014 Authors (incl. job title): Dr Moira Dick Consultant Paediatrician
Voxelotor, a First-in-Class Hemoglobin Oxygen Affinity Modulator
Interim Results From a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents With Sickle Cell Disease Treated with Multiple Doses of Voxelotor (GBT440) Voxelotor, a First-in-Class Hemoglobin Oxygen
Interleukin-1ß and Interleukin-6 Genetic Polymorphisms and Sickle Cell Disease: An Egyptian Study
Interleukin-1ß and Interleukin-6 Genetic Polymorphisms and Sickle Cell Disease: An Egyptian Study MONA EL-GHAMRAWY, MD, PROFESSOR OF PEDIATRICS & PEDIATRIC HEMATOLOGY, CAIRO UNIVERSITY melghamrawy95@gmail.com
Hydroxyurea for the Treatment of Sickle Cell Anemia
T h e n e w e ng l a nd j o u r na l o f m e dic i n e clinical therapeutics Hydroxyurea for the Treatment of Sickle Cell Anemia Orah S. Platt, M.D. This Journal feature begins with a case vignette that
Compassionate-use Voxelotor (GBT440) for up to 2 Years in Patients With Severe Sickle Cell Disease and Life-Threatening Comorbidities
Compassionate-use Voxelotor (GBT440) for up to 2 Years in Patients With Severe Sickle Cell Disease and Life-Threatening Comorbidities Gershwin Blyden, MD 1, Kenneth Bridges, MD 2, Lanetta Bronté, MD 1
Sickle Cell Disease an Overview
Sickle Cell Disease an Overview 11 th Annual Sickle Cell Disease and Thalassemia Conference 11 October 2017 Winfred Wang, MD St. Jude Children s Research Hospital Memphis, TN, USA Outline of Overview Sickle
Haemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD
Haemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD Introduction is the iron-containing oxygen transport metalloprotein in the red blood cells Hemoglobin in the blood carries oxygen from the respiratory organs
How to Increase Awareness Lanre Tunji-Ajayi. President/Executive Director; SCDAC/AAFC
How to Increase Awareness Lanre Tunji-Ajayi. President/Executive Director; SCDAC/AAFC September 20 th 2014 SICKLE CELL DISEASE ASSOCIATION OF CANADA ASSOCIATION D'ANEMIE FALCIFORME DU CANADA (SCDAC/AAFC)
Compassionate-use Experience With Voxelotor (GBT440) for Patients With Severe Sickle Cell Disease (SCD) and Life-Threatening Comorbidities
Compassionate-use Experience With Voxelotor (GBT440) for Patients With Severe Sickle Cell Disease (SCD) and Life-Threatening Comorbidities Gershwin Blyden, MD 1, Kenneth R. Bridges, MD 2, Lanetta Bronté,
Peri-Operative Management: Guidelines for Inpatient Management of Children with Sickle Cell Disease
Version 02 Approved by Interprofessional Patient Care Committee: September 16, 2016 1.0 Background Children with Sickle Cell are at risk of developing post-operative Acute Chest Syndrome. With improvements
4 Fahed Al Karmi Sufian Alhafez Dr nayef karadsheh
4 Fahed Al Karmi Sufian Alhafez Dr nayef karadsheh Genetic variants of hemoglobin Hemoglobinopathies (abnormal variants of hemoglobin) are divided into: 1. Structural abnormalities: Any change in the genes
Quiz. What percentage of the world s population is a carrier of a hemoglobinopathy? Hemoglobinopathies in Pregnancy 1-2% 5-7% 8-12% 10-15%
Hemoglobinopathies in Pregnancy Emily Parkhurst, MS, LCGC Kaiser West Los Angeles November 2017 Genetics Department Quiz What percentage of the world s population is a carrier of a hemoglobinopathy? 1-2%
High Hemoglobin F in a Saudi Child Presenting with Pancytopenia
Case Report imedpub Journals http://www.imedpub.com Journal of Pediatric Care ISSN 2471-805X DOI: 10.21767/2471-805X.100002 High Hemoglobin F in a Saudi Child Presenting with Pancytopenia Abstract Saudi
Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW
Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW Objectives Gain awareness of haemoglobinopathy inheritance, pathophysiology
Transfusion Practices and Creation of a Registry for Patients with Sickle Cell Disease within the Atlanta Sickle Cell Consortium
Transfusion Practices and Creation of a Registry for Patients with Sickle Cell Disease within the Atlanta Sickle Cell Consortium Annie Winkler MD Assistant Professor, Emory University Department of Pathology
Achieving a Better Understanding of the Impact of Sickle Cell in Indiana CHeP Pilot Project Symposium Gary Gibson Monica Khurana Marc Rosenman
Achieving a Better Understanding of the Impact of Sickle Cell in Indiana 2017 CHeP Pilot Project Symposium Gary Gibson Monica Khurana Marc Rosenman Primary Aims of Project Obtain much-needed estimates
HEMOGLOBINOPATHIES LECTURE OUTLINE. An overview of the structure of hemoglobin. Different types of hemoglobin. Definition of hemoglobinopathies
Slide 1 HEOGLOBINOPATHIES Slide 2 LETURE OUTLINE An overview of the structure of hemoglobin. Different types of hemoglobin. Definition of hemoglobinopathies Sickle ell Disease and Hemoglobin Slide 3 HEOGLOBIN
Original Research Article Ssafety and efficacy of prolonged hydroxycarbamide administration in adults with
1 1 2 3 Original Research Article Ssafety and efficacy of prolonged hydroxycarbamide administration in adults with sickle cell disease in Northwestern Greece 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Cover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/35456 holds various files of this Leiden University dissertation. Author: Hassan, Suha Mustafa Title: Toward prevention of Hemoglobinopathies in Oman Issue
Acute Chest Syndrome In A Patient With Sickle Cell Anemia Successfully Treated With Erythrocytapheresis
ISPUB.COM The Internet Journal of Emergency and Intensive Care Medicine Volume 9 Number 2 Acute Chest Syndrome In A Patient With Sickle Cell Anemia Successfully Treated With A Kararmaz, O Ayyildiz, S Kaya,
Long Term Effects of Hydroxyurea on Adult Patients with Sickle Cell Anemia
St. Catherine University SOPHIA Master of Arts in Nursing Theses Nursing 12-2012 Long Term Effects of Hydroxyurea on Adult Patients with Sickle Cell Anemia Christine R. Reimer St. Catherine University
Instructor s Manual Chapter 26 Hematological Alterations. 1. A man and woman both test positive for the sickle cell trait. The couple asks the
1 Instructor s Manual Chapter 26 Hematological Alterations Answers to Study Questions 1. A man and woman both test positive for the sickle cell trait. The couple asks the nurse how many of their children
RBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
RBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Discuss the classification of anemia into hypochromic-microcytic, normochromicnormocytic and macrocytic. Categorize laboratory test procedures used in the
Putting some hematology into Pediatric Hematology/Oncology: a review of Hemophilia and Sickle Cell Disease in the Pediatric Patient
Putting some hematology into Pediatric Hematology/Oncology: a review of Hemophilia and Sickle Cell Disease in the Pediatric Patient Kristina Haley, DO March 10, 2012 Jovita Reyes Memorial Pediatric Hematology/Oncology
CRISPR-mediated Editing of Hematopoietic Stem Cells for the Treatment of β-hemoglobinopathies
CRISPR-mediated Editing of Hematopoietic Stem Cells for the Treatment of β-hemoglobinopathies Jennifer Gori American Society of Gene & Cell Therapy May 11, 2017 editasmedicine.com 1 Highlights Developed
Extra Notes 3. Warm. In the core (center) of the body, where the temperature is 37 C.
Extra Notes 3 *The numbers of the slides are according to the last year slides. Slide 33 Autoimmune hemolytic anemia : Abnormal circulating antibodies that target normal antigen on the RBC and cause lysis.
Epidemiology, Care and Prevention of Hemoglobinopathies
Epidemiology, Care and Prevention of Hemoglobinopathies Nasir Al-Allawi MBChB, PhD. Professor of Hematology College of Medicine University of Dohuk, IRAQ From Research to Practice Training Course in Sexual
Newborn Screening and Followup for Hemoglobinopathies
Newborn Screening and Followup for Hemoglobinopathies October 4, 2012 Monica Hulbert, MD Director, Sickle Cell Disease Program Washington University School of Medicine St. Louis Children s Hospital Disclosures
Review each of the key concepts, considering. Look again at the initial case
Review each of the key concepts, considering Impact of pertinent biological processes Available evidence/experience, especially regarding interventions Myths and misconceptions Look again at the initial
PCOS. polycystic ovary syndrome BMI W/H PCOS. Generated by Foxit PDF Creator Foxit Software For evaluation only.
Tishreen University Journal for Research and Scientific Studies - Medical Sciences Series Vol. (30) No. ( ) 2008 * 2008 polycystic ovary syndrome W/H * ١٨٣ Generated by Foxit PDF Creator Foxit Software
Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89
Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89 Presented by Jennifer Kurkulonis 1 FOUR MAJOR TYPES OF BLOOD CELLS White blood cells
Chapter 1: Introduction and Methodology
Chapter 1: Introduction and Methodology These guidelines were developed by an expert panel composed of health care professionals with expertise in family medicine, general internal medicine, adult and
Sickle cell disease (SCD) was first described almost
SICKLE CELL DISEASE Advances in the use of hydroxyurea Russell E. Ware 1 and Banu Aygun 1 1 Department of Hematology, St. Jude Children s Research Hospital, Memphis TN Clinical experience with hydroxyurea
Genetic Modulation on the Phenotypic Diversity of Sickle Cell Disease
Genetic Modulation on the Phenotypic Diversity of Sickle Cell Disease Malay B. Mukherjee Abstract Sickle cell hemoglobin is a β chain structural variant where valine is substituted for glutamic acid in
Health Maintenance and Education for Children and Adults
Health Maintenance and Education for Children and Adults Richard Ward, MSc, MRCP, FRCPath Director, Red Blood Cell Disorders Program, UHN Assistant Professor, Hematology, University of Toronto Chair, Canadian
Pediatric Red Cell Exchange Indications, Benefits, Barriers. View from California Saturday May 9 th ASFA 2015
Pediatric Red Cell Exchange Indications, Benefits, Barriers View from California Saturday May 9 th ASFA 2015 Red Cell Exchange: Not SCD Recommendations for Red Cell Exchange Indication Procedure Recommendation
Approach to Hemolysis
Objectives: Approach to Hemolysis To know the function of platelets and the relationship between the platelet count in peripheral blood and the extent of abnormal bleeding. To know about the diseases associated